CL2018000853A1 - Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. - Google Patents
Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.Info
- Publication number
- CL2018000853A1 CL2018000853A1 CL2018000853A CL2018000853A CL2018000853A1 CL 2018000853 A1 CL2018000853 A1 CL 2018000853A1 CL 2018000853 A CL2018000853 A CL 2018000853A CL 2018000853 A CL2018000853 A CL 2018000853A CL 2018000853 A1 CL2018000853 A1 CL 2018000853A1
- Authority
- CL
- Chile
- Prior art keywords
- combination therapy
- control points
- treat cancer
- immune control
- bromodomain inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción proporciona una terapia de combinación de un inhibidor de bromodominios y un modulador inmunitario (por ejemplo, un inhibidor de puntos de control inmunitarios). La combinación del inhibidor de bromodominios y el modulador inmunitario puede ser útil en el tratamiento o la prevención del cáncer en un sujeto. En determinadas modalidades, el sujeto tiene un sistema inmunitario intacto. Se espera que la combinación del inhibidor de bromodominios y el modulador inmunitario sea sinérgica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562236280P | 2015-10-02 | 2015-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018000853A1 true CL2018000853A1 (es) | 2018-08-31 |
Family
ID=57137298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018000853A CL2018000853A1 (es) | 2015-10-02 | 2018-04-02 | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20190192532A1 (es) |
EP (1) | EP3355922A2 (es) |
JP (1) | JP2018530554A (es) |
KR (1) | KR20180081507A (es) |
CN (1) | CN108289957A (es) |
AR (1) | AR107500A1 (es) |
AU (1) | AU2016331190A1 (es) |
BR (1) | BR112018006689A2 (es) |
CA (1) | CA2999523A1 (es) |
CL (1) | CL2018000853A1 (es) |
HK (1) | HK1256269A1 (es) |
IL (1) | IL258212A (es) |
MA (1) | MA43037A (es) |
MX (1) | MX2018003824A (es) |
PE (1) | PE20181068A1 (es) |
WO (1) | WO2017059319A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101514463B1 (ko) * | 2005-06-08 | 2015-04-28 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
CA2723114C (en) | 2008-05-16 | 2018-02-27 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
WO2010025421A2 (en) | 2008-08-28 | 2010-03-04 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
ES2534521T3 (es) | 2010-05-14 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades |
JP5935030B2 (ja) | 2010-05-14 | 2016-06-15 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 白血病を治療するための組成物および方法 |
DK2877189T3 (da) | 2012-07-20 | 2021-02-22 | Taiga Biotechnologies Inc | Forbedret rekonstituering og autorekonstituering af det hæmopoietiske kammer |
MX2016005980A (es) | 2013-11-08 | 2016-12-09 | Dana Farber Cancer Inst Inc | Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal. |
WO2015131113A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
BR112018074463A2 (pt) | 2016-05-27 | 2019-03-06 | Agenus Inc. | anticorpos anti-tim-3 e métodos de uso dos mesmos. |
IL281425B (en) | 2016-12-02 | 2022-07-01 | Taiga Biotechnologies Inc | Nanoparticle formulations |
WO2019140953A1 (zh) * | 2018-01-16 | 2019-07-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用於治療三陰性乳癌之組合療法 |
JP2022516401A (ja) | 2018-11-30 | 2022-02-28 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
CN109666723B (zh) * | 2019-01-22 | 2022-04-15 | 南通大学 | 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用 |
AU2020274117A1 (en) * | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
WO2021011634A1 (en) * | 2019-07-15 | 2021-01-21 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
MX2022005029A (es) * | 2019-11-05 | 2022-07-12 | Resverlogix Corp | Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. |
US20230053152A1 (en) * | 2019-11-26 | 2023-02-16 | Benobio Co., Ltd. | Novel Quercetin Redox Derivative And Use Thereof As BET Inhibitor |
TW202136251A (zh) | 2019-12-17 | 2021-10-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
PE20231739A1 (es) | 2020-07-02 | 2023-10-31 | Incyte Corp | Compuestos triciclicos de urea como inhibidores de jak2 v617f |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010314395B2 (en) * | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
CA2799381A1 (en) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
ES2534521T3 (es) * | 2010-05-14 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades |
WO2012075456A1 (en) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
EP2958922A1 (de) * | 2013-02-22 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
CN105164135A (zh) * | 2013-02-22 | 2015-12-16 | 拜耳医药股份有限公司 | 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓 |
WO2014144721A2 (en) * | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Treating th2-mediated diseases by inhibition of bromodomains |
EP3030242A1 (en) * | 2013-08-06 | 2016-06-15 | Oncoethix GmbH | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
KR20160060765A (ko) * | 2013-10-11 | 2016-05-30 | 제넨테크, 인크. | 암 면역요법을 위한 cbp/ep300 브로모도메인 억제제의 용도 |
MX369491B (es) * | 2013-12-24 | 2019-11-11 | Bristol Myers Squibb Co | Compuestos tricíclicos como agentes anticancerígenos. |
-
2016
- 2016-09-30 BR BR112018006689A patent/BR112018006689A2/pt not_active IP Right Cessation
- 2016-09-30 MA MA043037A patent/MA43037A/fr unknown
- 2016-09-30 WO PCT/US2016/054924 patent/WO2017059319A2/en active Application Filing
- 2016-09-30 US US15/764,131 patent/US20190192532A1/en not_active Abandoned
- 2016-09-30 CA CA2999523A patent/CA2999523A1/en not_active Abandoned
- 2016-09-30 AU AU2016331190A patent/AU2016331190A1/en not_active Abandoned
- 2016-09-30 JP JP2018517255A patent/JP2018530554A/ja active Pending
- 2016-09-30 PE PE2018000491A patent/PE20181068A1/es unknown
- 2016-09-30 EP EP16781957.2A patent/EP3355922A2/en not_active Withdrawn
- 2016-09-30 MX MX2018003824A patent/MX2018003824A/es unknown
- 2016-09-30 CN CN201680070462.8A patent/CN108289957A/zh active Pending
- 2016-09-30 AR ARP160103015A patent/AR107500A1/es unknown
- 2016-09-30 KR KR1020187012018A patent/KR20180081507A/ko unknown
-
2018
- 2018-03-19 IL IL258212A patent/IL258212A/en unknown
- 2018-04-02 CL CL2018000853A patent/CL2018000853A1/es unknown
- 2018-11-29 HK HK18115329.0A patent/HK1256269A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017059319A2 (en) | 2017-04-06 |
BR112018006689A2 (pt) | 2018-10-09 |
WO2017059319A3 (en) | 2017-10-12 |
EP3355922A2 (en) | 2018-08-08 |
HK1256269A1 (zh) | 2019-09-20 |
AR107500A1 (es) | 2018-05-09 |
US20190192532A1 (en) | 2019-06-27 |
MX2018003824A (es) | 2019-04-01 |
AU2016331190A1 (en) | 2018-04-12 |
KR20180081507A (ko) | 2018-07-16 |
IL258212A (en) | 2018-05-31 |
CA2999523A1 (en) | 2017-04-06 |
JP2018530554A (ja) | 2018-10-18 |
CN108289957A (zh) | 2018-07-17 |
MA43037A (fr) | 2018-08-08 |
PE20181068A1 (es) | 2018-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000853A1 (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. | |
CY1123678T1 (el) | Χρηση αναστολεων μυοστατινης και θεραπειες συνδυασμου | |
CL2018003213A1 (es) | Inhibidores enzimáticos. | |
CL2018002708A1 (es) | Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita | |
MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
SV2017005380A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
CL2017002904A1 (es) | Métodos y kits para tratar la depresión | |
MX2017003227A (es) | Terapias de combinacion de inhibidores de alk. | |
BR112017018234A2 (pt) | inibidores de pd-1 / pd-l1 para o tratamento de câncer | |
BR112017008628A2 (pt) | terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit | |
CR20170219A (es) | Inhibidores del bromodominio | |
AR099619A1 (es) | Polímero viscosificante para el tratamiento de una formación subterránea | |
CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
MX2018006152A (es) | Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico. | |
CO2018013020A2 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
BR112017013982A2 (pt) | fármaco de combinação |